Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability 3-09-2024, 19:00

Arbor Metals Announces Lifting of Forest Entry Ban at St. James, Quebec, Canada 31-07-2023, 13:00

Fortinet Reports Third Quarter 2024 Financial Results 8-11-2024, 04:05